Univest
Univest
  • Markets
  • B. L. Kashyap and Sons Share Analyst Review: CMP, Performance, Target and 2026 Outlook

    • June 4, 2026
    • Posted by: Kunal Singla
    • Category: News
    No Comments
    B. L. Kashyap and Sons Share Analyst Review

    B. L. Kashyap and Sons share analyst review 2026: CMP Rs 54.39, 52-week range Rs 36.00-Rs 90.00, 12-month target Rs 68. Complete analyst review with sector outlook and risk assessment.

    read more
  • Blue Jet Healthcare Share Analyst Review: CMP, Performance, Target and 2026 Outlook

    • June 4, 2026
    • Posted by: Kunal Singla
    • Category: News
    No Comments
    Blue Jet Healthcare Share Analyst Review

    Blue Jet Healthcare share analyst review 2026: CMP Rs 452.50, 52-week range Rs 335.00-Rs 610.00, 12-month target Rs 566. Complete analyst review with sector outlook and risk assessment.

    read more
  • Enviro Infra Engineers Share Analyst Review: CMP, Performance, Target and 2026 Outlook

    • June 4, 2026
    • Posted by: Kunal Singla
    • Category: News
    No Comments
    Enviro Infra Engineers Share Analyst Review

    Enviro Infra Engineers share analyst review 2026: CMP Rs 187.54, 52-week range Rs 125.00-Rs 290.00, 12-month target Rs 234. Complete analyst review with sector outlook and risk assessment.

    read more
  • IFGL Refractories Q4 Results FY26: Revenue, PAT, Net Profit and Key Highlights

    • June 4, 2026
    • Posted by: Neeraj Pandey
    • Category: News
    No Comments
    IFGL Refractories Q4 Results FY26

    IFGL Refractories Q4 results for Q4 FY26: Revenue Rs 483 Cr (+8% YoY), net profit Rs 14 Cr (+75% YoY). Full financial highlights, performance analysis, FY27 outlook for IFGL Refractories.

    read more
  • Ducon Infratechnologies Share Analyst Review: CMP, Performance, Target and 2026 Outlook

    • June 4, 2026
    • Posted by: Kunal Singla
    • Category: News
    No Comments
    Ducon Infratechnologies Share Analyst Review

    Ducon Infratechnologies share analyst review 2026: CMP Rs 3.40, 52-week range Rs 1.80-Rs 5.20, 12-month target Rs 4. Complete analyst review with sector outlook and risk assessment.

    read more
  • Aarnav Fashions Q4 Results FY26: Revenue, PAT, Net Profit and Key Highlights

    • June 4, 2026
    • Posted by: Neeraj Pandey
    • Category: News
    No Comments
    Aarnav Fashions Q4 Results FY26

    Aarnav Fashions Q4 results for Q4 FY26: Revenue Rs 133 Cr (+46% YoY), net profit Rs 3 Cr (+200% YoY). Full financial highlights, performance analysis, FY27 outlook for Aarnav Fashions.

    read more
  • Alankit Share Analyst Review: CMP, Performance, Target and 2026 Outlook

    • June 4, 2026
    • Posted by: Kunal Singla
    • Category: News
    No Comments
    Alankit Share Analyst Review

    Alankit share analyst review 2026: CMP Rs 8.42, 52-week range Rs 5.80-Rs 15.00, 12-month target Rs 11. Complete analyst review with sector outlook and risk assessment.

    read more
  • Linde India Q4 Results FY26: Revenue, PAT, Net Profit and Key Highlights

    • June 4, 2026
    • Posted by: Neeraj Pandey
    • Category: News
    No Comments
    Linde India Q4 Results FY26

    Linde India Q4 results for Q4 FY26: Revenue Rs 614 Cr (+4% YoY), net profit Rs 77 Cr (-35% YoY). Full financial highlights, performance analysis, FY27 outlook for Linde India.

    read more
  • Thirumalai Chemicals Share Analyst Review: CMP, Performance, Target and 2026 Outlook

    • June 4, 2026
    • Posted by: Kunal Singla
    • Category: News
    No Comments
    Thirumalai Chemicals Share Analyst Review

    Thirumalai Chemicals share analyst review 2026: CMP Rs 186.44, 52-week range Rs 128.00-Rs 270.00, 12-month target Rs 233. Complete analyst review with sector outlook and risk assessment.

    read more
  • Aarey Drugs Q4 Results FY26: Revenue, PAT, Net Profit and Key Highlights

    • June 4, 2026
    • Posted by: Neeraj Pandey
    • Category: News
    No Comments
    Aarey Drugs Q4 Results FY26

    Aarey Drugs Q4 results for Q4 FY26: Revenue Rs 189 Cr (+75% YoY), net profit Rs 2 Cr (Turnaround YoY). Full financial highlights, performance analysis, FY27 outlook for Aarey Drugs.

    read more
  • 1
  • …
  • 1,095
  • 1,096
  • 1,097
  • 1,098
  • 1,099
  • …
  • 1,617